Literature DB >> 1971605

Long-term use of mesalamine enemas to induce remission in ulcerative colitis.

W L Biddle1, P B Miner.   

Abstract

The courses of 90 patients with left-sided ulcerative colitis that was unresponsive or intolerant to conventional therapy were retrospectively reviewed. They had been treated with 5-aminosalicylic acid enemas (mesalamine) on a long-term basis. After an initial 12-week course of treatment, 87% of the patients had improved by at least one grade of inflammation (improvement), and 54% of these were asymptomatic with normal colonic mucosa (remission). Overall, there was an 80% remission rate by 34 weeks. Remission rate was not affected by extent of sigmoid or left-sided colon disease before treatment or prior medication use for ulcerative colitis. Treatment with mesalamine enemas allowed patients to decrease or discontinue glucocorticoid treatment. Patients treated for relapse episodes responded as well as they did to the first course of treatment, whether the relapse occurred after discontinuation of mesalamine or during a tapering of the dose. In conclusion, extending mesalamine treatment to at least 34 weeks was beneficial in inducing a complete remission in 80% of patients unresponsive to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971605     DOI: 10.1016/0016-5085(90)91237-z

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Advantages in IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-05

Review 2.  A practical guide to the management of distal ulcerative colitis.

Authors:  S Ardizzone; G Bianchi Porro
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

3.  Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease.

Authors:  Chadwick Williams; Remo Panaccione; Subrata Ghosh; Kevin Rioux
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

Review 4.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

5.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

6.  Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.

Authors:  P Marteau; J Crand; M Foucault; J C Rambaud
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

Review 7.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.